Neal Meropol, MD, Division Chief, Hematology and Oncology - UH Cleveland Medical Center


Neal J. Meropol, MD is a medical oncologist and clinical researcher. He is the Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, and Chief of the Division of Hematology and Oncology at University Hospitals Cleveland Medical Center and Case Western Reserve University. He also serves as Associate Director for Clinical Research at the Case Comprehensive Cancer Center, and Associate Director for Clinical Programs at the University Hospitals Seidman Cancer Center. He is recognized by Cleveland Magazine in its “Best Doctors” issue, and by US News and World Report in its list of top 1% of physicians.
 
Dr. Meropol received his undergraduate degree from Princeton University in Philosophy, and MD from Vanderbilt University. He was a resident in Internal Medicine at Case Western Reserve University, and complete hematology and oncology fellowships at the University of Pennsylvania. He spent a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania. Dr. Meropol has a national reputation for his research contributions in gastrointestinal malignancies and health services research, including evaluation of new agents, predictors of response and outcome, and assessment of the economic impact of care. Dr. Meropol is also well-recognized for his research on patient decision making and doctor-patient communication, in particular with regard to clinical trials. He has extensively characterized the unique decision making calculus of cancer patients, and the drivers and barriers to clinical trial participation.

Download full bio


<< Back

You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.